Xoma Corporation

Jenner Technologies

University of California

Jenner Biotherapies, Inc.

Lynn E Spitler

Carl R Alving

Patrick J Scannon

Ronald P Mischak

Jean M Muderhwa

Alan S Levin

Anthony E Maida, Iii

Daniel P Stites

Howard M Lee

Russell T Kawahata

H Hugh Fudenberg

A composition which comprises a stable oil-in-water emulsion having a continuous water phase and a discontinuous oil phase and containing, as sole stabilizing agent, a sufficient quantity of smectic mesophase vesicles and their disintegrated forms to provide at least about 100 mM amphiphile is stable and useful as an adjuvant, in a vaccine, or drug delivery system

Immunogenic compositions

Vaccines capable of eliciting an immune antitumor response for prostate tumors are disclosed. The active ingredient in such vaccines is selected from the group consisting of human PSA and expression system capable of generating in situ human PSA.

Method to elicit an antitumor response with human prostate-specific

Antitumor vaccine compositions and methods for treating tumors that express the GA733-2 antigen are disclosed. The vaccines comprise a GS733-2 antigen in a liposomal carrier.

Antitumor vaccines

Conjugates of monoclonal antibodies specific to human melanoma and the A chain of a toxic lectin such as ricin or an equivalent ribosomal inhibiting protein. The conjugate is synthesized by a novel process employing anti-toxic lectin B chain antibodies to remove lectin B chain impurities and provide a highly purified conjugate that is non-toxic to cells other than melanoma. The conjugates are used to treat human melanoma. The hybridomas XMMME-001 and XMMME-002 were deposited with the American Type Culture Collection (A.T.C.C.) on Mar. 26, 1985, and given A.T.C.C. Accession Nos. HB8759 and HB8760, respectively.

Human melanoma specific immunotoxins

An improved transplantion therapy and method is provided which comprises specifically killing cells known to be problematic in the transplantion process. Novel compositions of the present invention are conjugates prepared by generating antibodies specific to surface receptors of the unwanted cells, preparing Fab or F(ab').sub.2 fragments from the antibodies, and coupling the fragments to A chains of lectins or other cytotoxic agents to render the conjugates thus formed strongly cytotoxic to the cells to which the antibody was directed. The conjugates are used in vitro to eliminate unwanted cells prior to bone marrow transplantation.

Composition and method for transplantation therapy

A method of treating human patients suffering from immune deficiency diseases by extracting a 'transfer factor' from leucocytes obtained from healthy donors who exhibit immune response to said diseases and injecting said 'transfer factor' into said diseased patients to thereby suppress disease symptoms.

Growing community of inventors

Tiburon, CA, United States of America

Lynn E Spitler